FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFI	ICIAL C	WNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Thompson Rahsaan				2. Issuer Name and Ticker or Trading Symbol  Lyell Immunopharma, Inc. [ LYEL ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner     Officer (give title Other (spe				ner	
(Last) (First) (Middle) C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY				3. Date of Earliest Transaction (Month/Day/Year) 02/24/2023								X Officer (give title below)  Chief Legal Officer					
(Street) SOUTH FRANIC	SAN SCO C.	A	94080 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	idividual or Joint/Group Filing (Check Applicable )  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Ta	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired,	Dis	osed o	of, or Be	neficiall	y Owned				
Date			Transaction te onth/Day/	Execution Date		Date,	e, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficia Owned F	Forr lly (D) o ollowing (I) (I	Form (D) or	n: Direct I or Indirect E nstr. 4) (	7. Nature of ndirect Beneficial Dwnership		
						Code	v	Amount	(A) o (D)	r Price		saction(s) r. 3 and 4)			nstr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security  2. Conversion or Exercise (Month/Day/Year)  3. Transaction Date Execution Date, if any (Month/Day/Year)		Code	ransaction Derivative Sode (Instr. Securities		e s l (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Option (right to buy)	\$2.13	02/24/2023		A		245,000		(1)	0	2/23/2033	Common Stock	245,000	\$0.00	245,00	00	D	

## **Explanation of Responses:**

1. 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

## Remarks:

/s/ Hector Casab, as Attorney-

02/28/2023

in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.